CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Operating Margin
- Operating margin · 12 months: Value 2.25%; Formula and calculation Operating income / revenue. Period ending 2026-06-27..
Operating margin
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 2.25% | Operating income / revenue. Period ending 2026-06-27. $90.14M ÷ $4.00B × 100 ≈ 2.25% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 90.14M USD | Operating Income (Loss) |
| Revenue | 4.00B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 762.04M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-27 | $90.14M | $4.00B | (m) | (m) | $762.04M | 2.25% |
| 2026-03-28 | $70.39M | $4.03B | (m) | (m) | $724.70M | 1.75% |
| 2025-12-27 | $25.16M | $4.02B | (m) | (m) | $743.07M | 0.63% |
| 2025-09-27 | $140.91M | $4.02B | (m) | (m) | $742.64M | 3.50% |
| 2025-06-28 | $124.52M | $4.03B | (m) | (m) | $764.27M | 3.09% |
| 2025-03-29 | $176.04M | $4.02B | (m) | (m) | $742.51M | 4.38% |
| 2024-12-28 | $227.35M | $4.05B | (m) | (m) | $751.00M | 5.61% |
| 2024-09-28 | $527.96M | $4.06B | (m) | (m) | $752.44M | 13.00% |
| 2024-06-29 | $562.05M | $4.08B | (m) | (m) | $729.33M | 13.78% |
| 2024-03-30 | $575.35M | $4.11B | (m) | (m) | $759.30M | 13.99% |
| 2023-12-30 | $617.26M | $4.13B | (m) | (m) | $747.86M | 14.95% |
| 2023-09-30 | $648.15M | $4.22B | (m) | (m) | $750.35M | 15.37% |
| 2023-07-01 | $647.62M | $4.18B | (m) | (m) | $757.96M | 15.50% |
| 2023-04-01 | $670.09M | $4.09B | (m) | (m) | $689.91M | 16.38% |
| 2022-12-31 | $650.98M | $3.98B | (m) | (m) | $665.10M | 16.37% |
| 2022-09-24 | $659.97M | $3.78B | (m) | (m) | $609.57M | 17.45% |
| 2022-06-25 | $664.80M | $3.69B | (m) | (m) | $574.43M | 18.03% |
| 2022-03-26 | $614.94M | $3.63B | (m) | (m) | $614.22M | 16.94% |
| 2021-12-25 | $589.86M | $3.54B | (m) | (m) | $619.92M | 16.66% |
| 2021-09-25 | $545.98M | $3.43B | (m) | (m) | $618.84M | 15.94% |
| 2021-06-26 | $522.93M | $3.27B | (m) | (m) | $598.56M | 15.97% |
| 2021-03-27 | $462.15M | $3.04B | (m) | (m) | $554.77M | 15.20% |
| 2020-12-26 | $432.73M | $2.92B | (m) | (m) | $528.93M | 14.80% |
| 2020-09-26 | $412.59M | $2.82B | (m) | (m) | $515.50M | 14.61% |
| 2020-06-27 | $372.64M | $2.75B | (m) | (m) | $516.72M | 13.56% |
| 2020-03-28 | $375.64M | $2.72B | (m) | (m) | $524.95M | 13.79% |
| 2019-12-28 | $351.15M | $2.62B | (m) | (m) | $517.62M | 13.40% |
| 2019-09-28 | $344.84M | $2.53B | (m) | (m) | $494.94M | 13.62% |
| 2019-06-29 | $336.40M | $2.45B | (m) | (m) | $478.47M | 13.74% |
| 2019-03-30 | $333.35M | $2.38B | (m) | (m) | $463.06M | 14.03% |
| 2018-12-29 | $331.38M | $2.27B | (m) | (m) | $443.85M | 14.62% |
| 2018-09-29 | $290.94M | $2.14B | (m) | (m) | $433.23M | 13.58% |
| 2018-06-30 | $280.64M | $2.02B | (m) | (m) | $412.62M | 13.88% |
| 2018-03-31 | $285.62M | $1.91B | (m) | (m) | $385.91M | 14.99% |
| 2017-12-30 | $287.50M | $1.86B | (m) | (m) | $373.45M | 15.48% |
| 2017-09-30 | $293.86M | $1.85B | (m) | (m) | $377.37M | 15.92% |
| 2017-07-01 | $278.67M | $1.81B | (m) | (m) | $370.15M | 15.42% |
| 2017-04-01 | $255.42M | $1.77B | (m) | (m) | $376.09M | 14.41% |
| 2016-12-31 | $237.42M | $1.68B | (m) | (m) | $367.55M | 14.12% |
| 2016-09-24 | $220.60M | $1.57B | (m) | (m) | $350.53M | 14.06% |
| 2016-06-25 | $217.24M | $1.49B | (m) | (m) | $341.10M | 14.56% |
| 2016-03-26 | $214.92M | $1.40B | (m) | (m) | $311.96M | 15.38% |
| 2015-12-26 | $206.45M | $1.36B | (m) | (m) | $300.41M | 15.14% |
| 2015-09-26 | $194.95M | $1.34B | (m) | (m) | $290.99M | 14.56% |
| 2015-06-27 | $185.68M | $1.32B | (m) | (m) | $279.24M | 14.10% |
| 2015-03-28 | $180.97M | $1.32B | (m) | (m) | $275.66M | 13.72% |
| 2014-12-27 | $177.67M | $1.30B | (m) | (m) | $269.03M | 13.69% |
| 2014-09-27 | $161.51M | $1.26B | (m) | (m) | $255.67M | 12.85% |
| 2014-06-28 | $156.18M | $1.22B | (m) | (m) | $246.10M | 12.78% |
| 2014-03-29 | $148.34M | $1.17B | (m) | (m) | $233.26M | 12.64% |
| 2013-12-28 | $151.40M | $1.17B | (m) | (m) | $225.69M | 12.99% |
| 2013-09-28 | $161.86M | $1.16B | (m) | (m) | $218.34M | 14.00% |
| 2013-06-29 | $158.70M | $1.14B | (m) | (m) | $214.49M | 13.88% |
| 2013-03-30 | $164.79M | $1.13B | (m) | (m) | $209.47M | 14.52% |
| 2012-12-29 | $165.76M | $1.13B | (m) | (m) | $208.25M | 14.68% |
| 2012-09-29 | $172.34M | $1.14B | (m) | (m) | $203.01M | 15.11% |
| 2012-06-30 | $171.75M | $1.14B | (m) | (m) | $202.31M | 15.08% |
| 2012-03-31 | $175.79M | $1.14B | (m) | (m) | $199.62M | 15.38% |
| 2011-12-31 | $174.31M | $1.14B | (m) | (m) | $198.65M | 15.25% |
| 2011-09-24 | $-232.50M | $1.13B | (m) | (m) | $208.49M | -20.51% |
| 2011-06-25 | $-263.13M | $1.13B | (m) | (m) | $207.13M | -23.35% |
| 2011-03-26 | $-286.45M | $1.13B | (m) | (m) | $225.16M | -25.42% |
| 2010-12-25 | $-298.51M | $1.13B | (m) | (m) | $232.49M | -26.34% |
| 2010-09-25 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-26 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-27 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-26 | $169.61M | $1.17B | (m) | (m) | $227.66M | 14.48% |
| 2009-09-26 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-27 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-27 | $-451.84M | $1.30B | (m) | (m) | $223.94M | -34.88% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |